Skip to main content
Clinical Trials/DRKS00014360
DRKS00014360Not yet recruitingPhase 2

Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study. - NOV FR04

niversitätsklinikum Freiburg0 sites30 target enrollmentStarted: May 10, 2019Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
14 Years to 20 Years (—)
Sex
Female

Inclusion Criteria

  • DSM 5 (307.1) for Anorexia nervosa
  • Amenorrhea for a minimum of 3 months preceding study participation
  • Age 14-20 years
  • Bone age = 14 years
  • BMI-Percentile = 5%

Exclusion Criteria

  • Primary amenorrhea
  • Premature ovarian failure, as demonstrated by an elevated FSH
  • Diseases known to affect bone metabolism including:
  • -untreated thyreoid disease
  • -cushing syndrome
  • -pituitary disease
  • -renal failure
  • -prior bone fracture within 6 months of the study
  • Medication known to affect bone metabolism (including gonadal steroids within the last 3 months)
  • Evidence of:
  • -Suicidality
  • -Psychosis
  • -Substance abuse
  • Abnormal TSH
  • Hematocrit < 30%
  • Potassium < 3,0 mmol/l
  • Glucose < 50 mg/dl
  • Pregnancy/lactation
  • History of malignancy
  • Contraindications to estrogen therapy (for girls with AN)

Investigators

Similar Trials